1
|
Bottcher SE, Lou J, Best MD. Liposome triggered content release through molecular recognition of inositol trisphosphate. Chem Commun (Camb) 2022; 58:4520-4523. [PMID: 35302139 DOI: 10.1039/d2cc00951j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
A stimuli-responsive liposomal platform that is selectively activated by inositol 1,4,5-trisphosphate (IP3) over eleven other phosphorylated metabolites is reported. Dye release assays validated dose-dependent release of both hydrophilic and hydrophobic cargo driven by IP3, showcasing the potential of this platform for triggered release and sensing applications.
Collapse
Affiliation(s)
- Sydney E Bottcher
- Department of Chemistry, University of Tennessee, Knoxville, TN, 37996, USA.
| | - Jinchao Lou
- Department of Chemistry, University of Tennessee, Knoxville, TN, 37996, USA.
| | - Michael D Best
- Department of Chemistry, University of Tennessee, Knoxville, TN, 37996, USA.
| |
Collapse
|
2
|
Li Y, Ye Z, Yang H, Xu Q. Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs. Acta Pharm Sin B 2022; 12:2624-2639. [PMID: 35755280 PMCID: PMC9214058 DOI: 10.1016/j.apsb.2022.04.013] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 03/17/2022] [Accepted: 04/11/2022] [Indexed: 12/15/2022] Open
Affiliation(s)
- Yamin Li
- Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
- Department of Pharmacology, State University of New York, Upstate Medical University, Syracuse, NY 13210, USA
| | - Zhongfeng Ye
- Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
| | - Hanyi Yang
- Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
| | - Qiaobing Xu
- Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
- Corresponding author.
| |
Collapse
|
3
|
Xue Y, Bai H, Peng B, Tieu T, Jiang J, Hao S, Li P, Richardson M, Baell J, Thissen H, Cifuentes A, Li L, Voelcker NH. Porous Silicon Nanocarriers with Stimulus-Cleavable Linkers for Effective Cancer Therapy. Adv Healthc Mater 2022; 11:e2200076. [PMID: 35306736 DOI: 10.1002/adhm.202200076] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 02/19/2022] [Indexed: 12/13/2022]
Abstract
Porous silicon nanoparticles (pSiNPs) are widely utilized as drug carriers due to their excellent biocompatibility, large surface area, and versatile surface chemistry. However, the dispersion in pore size and biodegradability of pSiNPs arguably have hindered the application of pSiNPs for controlled drug release. Here, a step-changing solution to this problem is described involving the design, synthesis, and application of three different linker-drug conjugates comprising anticancer drug doxorubicin (DOX) and different stimulus-cleavable linkers (SCLs) including the photocleavable linker (ortho-nitrobenzyl), pH-cleavable linker (hydrazone), and enzyme-cleavable linker (β-glucuronide). These SCL-DOX conjugates are covalently attached to the surface of pSiNP via copper (I)-catalyzed alkyne-azide cycloaddition (CuAAC, i.e., click reaction) to afford pSiNP-SCL-DOXs. The mass loading of the covalent conjugation approach for pSiNP-SCL-DOX reaches over 250 µg of DOX per mg of pSiNPs, which is notably twice the mass loading achieved by noncovalent loading. Moreover, the covalent conjugation between SCL-DOX and pSiNPs endows the pSiNPs with excellent stability and highly controlled release behavior. When tested in both in vitro and in vivo tumor models, the pSiNP-SCL-DOXs induces excellent tumor growth inhibition.
Collapse
Affiliation(s)
- Yufei Xue
- Frontiers Science Center for Flexible Electrons Xi'an institute of Flexible Electrons (IFE) and Xi'an institute of Biomedical Materials and Engineering Northwestern Polytechnical University (NPU) 127 West Youyi Road Xi'an 710072 China
- Drug Delivery, Disposition and Dynamics Monash institute of Pharmaceutical Sciences Monash University Parkville Victoria 3052 Australia
| | - Hua Bai
- Frontiers Science Center for Flexible Electrons Xi'an institute of Flexible Electrons (IFE) and Xi'an institute of Biomedical Materials and Engineering Northwestern Polytechnical University (NPU) 127 West Youyi Road Xi'an 710072 China
| | - Bo Peng
- Frontiers Science Center for Flexible Electrons Xi'an institute of Flexible Electrons (IFE) and Xi'an institute of Biomedical Materials and Engineering Northwestern Polytechnical University (NPU) 127 West Youyi Road Xi'an 710072 China
- Drug Delivery, Disposition and Dynamics Monash institute of Pharmaceutical Sciences Monash University Parkville Victoria 3052 Australia
| | - Terence Tieu
- Drug Delivery, Disposition and Dynamics Monash institute of Pharmaceutical Sciences Monash University Parkville Victoria 3052 Australia
| | - Jiamin Jiang
- Frontiers Science Center for Flexible Electrons Xi'an institute of Flexible Electrons (IFE) and Xi'an institute of Biomedical Materials and Engineering Northwestern Polytechnical University (NPU) 127 West Youyi Road Xi'an 710072 China
| | - Shiping Hao
- Frontiers Science Center for Flexible Electrons Xi'an institute of Flexible Electrons (IFE) and Xi'an institute of Biomedical Materials and Engineering Northwestern Polytechnical University (NPU) 127 West Youyi Road Xi'an 710072 China
| | - Panpan Li
- Frontiers Science Center for Flexible Electrons Xi'an institute of Flexible Electrons (IFE) and Xi'an institute of Biomedical Materials and Engineering Northwestern Polytechnical University (NPU) 127 West Youyi Road Xi'an 710072 China
| | - Mark Richardson
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Clayton Victoria 3168 Australia
| | - Jonathan Baell
- Drug Delivery, Disposition and Dynamics Monash institute of Pharmaceutical Sciences Monash University Parkville Victoria 3052 Australia
| | - Helmut Thissen
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Clayton Victoria 3168 Australia
| | - Anna Cifuentes
- Drug Delivery, Disposition and Dynamics Monash institute of Pharmaceutical Sciences Monash University Parkville Victoria 3052 Australia
| | - Lin Li
- Frontiers Science Center for Flexible Electrons Xi'an institute of Flexible Electrons (IFE) and Xi'an institute of Biomedical Materials and Engineering Northwestern Polytechnical University (NPU) 127 West Youyi Road Xi'an 710072 China
| | - Nicolas H. Voelcker
- Frontiers Science Center for Flexible Electrons Xi'an institute of Flexible Electrons (IFE) and Xi'an institute of Biomedical Materials and Engineering Northwestern Polytechnical University (NPU) 127 West Youyi Road Xi'an 710072 China
- Drug Delivery, Disposition and Dynamics Monash institute of Pharmaceutical Sciences Monash University Parkville Victoria 3052 Australia
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Clayton Victoria 3168 Australia
- Melbourne Centre for Nanofabrication Victorian Node of the Australian National Fabrication Facility Clayton Victoria 3168 Australia
- Department of Materials Science and Engineering Monash University Clayton Victoria 3168 Australia
| |
Collapse
|
4
|
Mena-Giraldo P, Orozco J. Polymeric Micro/Nanocarriers and Motors for Cargo Transport and Phototriggered Delivery. Polymers (Basel) 2021; 13:3920. [PMID: 34833219 PMCID: PMC8621231 DOI: 10.3390/polym13223920] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Revised: 11/08/2021] [Accepted: 11/09/2021] [Indexed: 02/07/2023] Open
Abstract
Smart polymer-based micro/nanoassemblies have emerged as a promising alternative for transporting and delivering a myriad of cargo. Cargo encapsulation into (or linked to) polymeric micro/nanocarrier (PC) strategies may help to conserve cargo activity and functionality when interacting with its surroundings in its journey to the target. PCs for cargo phototriggering allow for excellent spatiotemporal control via irradiation as an external stimulus, thus regulating the delivery kinetics of cargo and potentially increasing its therapeutic effect. Micromotors based on PCs offer an accelerated cargo-medium interaction for biomedical, environmental, and many other applications. This review collects the recent achievements in PC development based on nanomicelles, nanospheres, and nanopolymersomes, among others, with enhanced properties to increase cargo protection and cargo release efficiency triggered by ultraviolet (UV) and near-infrared (NIR) irradiation, including light-stimulated polymeric micromotors for propulsion, cargo transport, biosensing, and photo-thermal therapy. We emphasize the challenges of positioning PCs as drug delivery systems, as well as the outstanding opportunities of light-stimulated polymeric micromotors for practical applications.
Collapse
Affiliation(s)
| | - Jahir Orozco
- Max Planck Tandem Group in Nanobioengineering, Institute of Chemistry, Faculty of Natural and Exact Sciences, University of Antioquia, Complejo Ruta N, Calle 67 # 52-20, Medellin 050010, Colombia;
| |
Collapse
|
5
|
Qiu M, Li Y, Bloomer H, Xu Q. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing. Acc Chem Res 2021; 54:4001-4011. [PMID: 34668716 DOI: 10.1021/acs.accounts.1c00500] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Since the U.S. Food and Drug Administration (FDA) granted emergency use authorization for two mRNA vaccines against SARS-CoV-2, mRNA-based technology has attracted broad attention from the scientific community to investors. When delivered intracellularly, mRNA has the ability to produce various therapeutic proteins, enabling the treatment of a variety of illnesses, including but not limited to infectious diseases, cancers, and genetic diseases. Accordingly, mRNA holds significant therapeutic potential and provides a promising means to target historically hard-to-treat diseases. Current clinical efforts harnessing mRNA-based technology are focused on vaccination, cancer immunotherapy, protein replacement therapy, and genome editing. The clinical translation of mRNA-based technology has been made possible by leveraging nanoparticle delivery methods. However, the application of mRNA for therapeutic purposes is still challenged by the need for specific, efficient, and safe delivery systems.This Account highlights key advances in designing and developing combinatorial synthetic lipid nanoparticles (LNPs) with distinct chemical structures and properties for in vitro and in vivo intracellular mRNA delivery. LNPs represent the most advanced nonviral nanoparticle delivery systems that have been extensively investigated for nucleic acid delivery. The aforementioned COVID-19 mRNA vaccines and one LNP-based small interfering RNA (siRNA) drug (ONPATTRO) have received clinical approval from the FDA, highlighting the success of synthetic ionizable lipids for in vivo nucleic acid delivery. In this Account, we first summarize the research efforts from our group on the development of bioreducible and biodegradable LNPs by leveraging the combinatorial chemistry strategy, such as the Michael addition reaction, which allows us to easily generate a large set of lipidoids with diverse chemical structures. Next, we discuss the utilization of a library screening strategy to identify optimal LNPs for targeted mRNA delivery and showcase the applications of the optimized LNPs in cell engineering and genome editing. Finally, we outline key challenges to the clinical translation of mRNA-based therapies and propose an outlook for future directions of the chemical design and optimization of LNPs to improve the safety and specificity of mRNA drugs. We hope this Account provides insight into the rational design of LNPs for facilitating the development of mRNA therapeutics, a transformative technology that promises to revolutionize future medicine.
Collapse
Affiliation(s)
- Min Qiu
- Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, Massachusetts 02155, United States
| | - Yamin Li
- Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, Massachusetts 02155, United States
| | - Hanan Bloomer
- Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, Massachusetts 02155, United States
- School of Medicine & Graduate School of Biomedical Sciences, Tufts University, Boston, Massachusetts 02111, United States
| | - Qiaobing Xu
- Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, Massachusetts 02155, United States
| |
Collapse
|
6
|
Tomé I, Francisco V, Fernandes H, Ferreira L. High-throughput screening of nanoparticles in drug delivery. APL Bioeng 2021; 5:031511. [PMID: 34476328 PMCID: PMC8397474 DOI: 10.1063/5.0057204] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 07/30/2021] [Indexed: 12/19/2022] Open
Abstract
The use of pharmacologically active compounds to manage and treat diseases is of utmost relevance in clinical practice. It is well recognized that spatial-temporal control over the delivery of these biomolecules will greatly impact their pharmacokinetic profile and ultimately their therapeutic effect. Nanoparticles (NPs) prepared from different materials have been tested successfully in the clinic for the delivery of several biomolecules including non-coding RNAs (siRNA and miRNA) and mRNAs. Indeed, the recent success of mRNA vaccines is in part due to progress in the delivery systems (NP based) that have been developed for many years. In most cases, the identification of the best formulation was done by testing a small number of novel formulations or by modification of pre-existing ones. Unfortunately, this is a low throughput and time-consuming process that hinders the identification of formulations with the highest potential. Alternatively, high-throughput combinatorial design of NP libraries may allow the rapid identification of formulations with the required release and cell/tissue targeting profile for a given application. Combinatorial approaches offer several advantages over conventional methods since they allow the incorporation of multiple components with varied chemical properties into materials, such as polymers or lipid-like materials, that will subsequently form NPs by self-assembly or chemical conjugation processes. The current review highlights the impact of high-throughput in the development of more efficient drug delivery systems with enhanced targeting and release kinetics. It also describes the current challenges in this research area as well as future directions.
Collapse
Affiliation(s)
| | - Vitor Francisco
- Biomaterials and Stem-Cell Based Therapeutics Group, Centre of Neuroscience and Cell Biology, University of Coimbra, 3060-197 Cantanhede, Portugal
| | | | | |
Collapse
|
7
|
Li Y, Li P, Li R, Xu Q. Intracellular Antibody Delivery Mediated by Lipids, Polymers, and Inorganic Nanomaterials for Therapeutic Applications. ADVANCED THERAPEUTICS 2020. [DOI: 10.1002/adtp.202000178] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Yamin Li
- Department of Biomedical Engineering Tufts University Medford MA 02155 USA
| | - Peixuan Li
- Department of Biomedical Engineering Tufts University Medford MA 02155 USA
| | - Raissa Li
- Department of Biomedical Engineering Tufts University Medford MA 02155 USA
| | - Qiaobing Xu
- Department of Biomedical Engineering Tufts University Medford MA 02155 USA
| |
Collapse
|
8
|
Li Y, Li R, Chakraborty A, Ogurlu R, Zhao X, Chen J, Xu Q. Combinatorial Library of Cyclic Benzylidene Acetal-Containing pH-Responsive Lipidoid Nanoparticles for Intracellular mRNA Delivery. Bioconjug Chem 2020; 31:1835-1843. [PMID: 32520527 DOI: 10.1021/acs.bioconjchem.0c00295] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Lipidoid nanoparticles have been demonstrated to be effective for intracellular delivery of small molecule drugs, proteins, and nucleic acids. Stimuli-responsive lipidoid nanoparticles are able to further improve delivery efficacy and reduce carrier-induced toxicity. Our group previously developed reduction and photoresponsive combinatorial libraries of lipidoid nanoparticles for small molecule and biologics delivery. Herein, we describe the synthesis, characterization, and intracellular mRNA delivery application of a new library of pH-responsive lipidoid nanoparticles. The acid-degradable cyclic benzylidene acetal-containing cationic lipidoids (R-O16CBA) were synthesized through a multistep reaction and characterized by NMR and MS. The acid-triggered degradation of lipidoids was studied using NMR, MS, DLS, and TEM. The results revealed that the R-O16CBA lipidoid can be completely degraded at pH 5. The R-O16CBA lipidoid nanoparticles were then fabricated with different formulations of DOPE and cholesterol and tested in vitro for intracellular mRNA delivery.
Collapse
Affiliation(s)
- Yamin Li
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States
| | - Raissa Li
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States
| | - Anirban Chakraborty
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States
| | - Roza Ogurlu
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States
| | - Xuewei Zhao
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States
| | - Jinjin Chen
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States
| | - Qiaobing Xu
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States
| |
Collapse
|
9
|
Li Y, Glass Z, Huang M, Chen ZY, Xu Q. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications. Biomaterials 2020; 234:119711. [PMID: 31945616 PMCID: PMC7035593 DOI: 10.1016/j.biomaterials.2019.119711] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 12/17/2019] [Accepted: 12/18/2019] [Indexed: 12/20/2022]
Abstract
The recently developed CRISPR/Cas9 technology has revolutionized the genome engineering field. Since 2016, increasing number of studies regarding CRISPR therapeutics have entered clinical trials, most of which are focusing on the ex vivo genome editing. In this review, we highlight the ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications. In these studies, CRISPR/Cas9 tools were used to edit cells in vitro and the successfully edited cells were considered as therapeutics, which can be introduced into patients to treat diseases. Considering a large number of previous reviews have been focused on the CRISPR/Cas9 delivery methods and materials, this review provides a different perspective, by mainly introducing the targeted conditions and design strategies for ex vivo CRISPR/Cas9 therapeutics. Brief descriptions of the history, functionality, and applications of CRISPR/Cas9 systems will be introduced first, followed by the design strategies and most significant results from previous research that used ex vivo CRISPR/Cas9 genome editing for the treatment of conditions or diseases. The last part of this review includes general information about the status of CRISPR/Cas9 therapeutics in clinical trials. We also discuss some of the challenges as well as the opportunities in this research area.
Collapse
Affiliation(s)
- Yamin Li
- Department of Biomedical Engineering, Tufts University, Medford, MA, 02155, USA
| | - Zachary Glass
- Department of Biomedical Engineering, Tufts University, Medford, MA, 02155, USA
| | - Mingqian Huang
- Eaton-Peabody Laboratory, Massachusetts Eye and Ear, Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, 02114, USA
| | - Zheng-Yi Chen
- Eaton-Peabody Laboratory, Massachusetts Eye and Ear, Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, 02114, USA.
| | - Qiaobing Xu
- Department of Biomedical Engineering, Tufts University, Medford, MA, 02155, USA.
| |
Collapse
|